Pozzi E
Department of Clinical and Biological Sciences, University of Turin, Italy.
J Antimicrob Chemother. 1993 Mar;31 Suppl C:153-8. doi: 10.1093/jac/31.suppl_c.153.
A multicentre trial was carried out to compare the efficacy and safety of dirithromycin with miocamycin in the treatment of patients with acute bronchitis or acute exacerbations of chronic bronchitis. The study was a single-blind, randomized, parallel-group study. Dirithromycin was administered orally at a dosage of 500 mg once daily and miocamycin was administered orally at a dosage of 600 mg twice daily; the duration of therapy was five to seven days for both drugs. The results, in 161 assessable patients (78 taking dirithromycin; 83 taking miocamycin), show that dirithromycin and miocamycin have comparable efficacy and safety in the treatment of bronchitis caused by susceptible bacterial pathogens.
开展了一项多中心试验，比较地红霉素与米卡霉素治疗急性支气管炎或慢性支气管炎急性加重患者的疗效和安全性。该研究为单盲、随机、平行组研究。地红霉素口服给药，剂量为每日500mg，一次服用；米卡霉素口服给药，剂量为每日600mg，分两次服用；两种药物的治疗疗程均为5至7天。161例可评估患者（78例服用地红霉素；83例服用米卡霉素）的结果表明，地红霉素和米卡霉素在治疗由敏感细菌病原体引起的支气管炎方面具有相当的疗效和安全性。
